Innate Pharma And Sanofi's Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress
Innate Pharma And Sanofi's Blood Cancer Treatment SAR443579/IPH6101 Shows Over 10 Months Of Durable Complete Remission In Phase 1/2 Study, Results Discussed At EHA Congress
innate pharma和賽諾菲的血液癌症治療SAR443579/IPH6101在1/2期研究中表現超過10個月的持久完全緩解，結果在EHA大會上討論。
- SAR443579/IPH6101, ANKET platform lead asset, is a first-in-class NKp46/CD16-based NK cell engager targeting CD123 from a joint research collaboration between Innate Pharma and Sanofi, under development by Sanofi in R/R AML, B-ALL and HR-MDS
- SAR443579/IPH6101 continues to show clinical benefit and durable responses along with a favorable safety profile in patients with R/R AML, with 5 complete remissions (4 CR / 1 CRi) achieved at 1 mg/kg, with durable CR (>10 months) observed in 3 patient
- "We are pleased to see that SAR'579 continues to show promising and durable clinical efficacy along with a favorable safety profile. The ongoing Phase 1/2 study has recently progressed to the Phase 2 stage, marking a significant milestone in its development. We look forward to the continued progress of this multi-specific NK Cell Engager which holds great potential to benefit patients suffering from various blood cancers," says Dr Sonia Quaratino, Chief Medical Officer of Innate Pharma.
- SAR443579/IPH6101，ANKET平台的領先資產，是首個基於NKp46/CD16的NK細胞結合劑，其靶向CD123，由Innate Pharma和賽諾菲共同研發，由賽諾菲在R / R AML，B-ALL和HR-MDS中進行開發。
- SAR443579/IPH6101在R/R AML患者中繼續顯示出臨床效益和持久療效，同時具有良好的安全性。在1mg / kg下取得5個完全緩解（4 CR / 1 CRi），在3個患者中觀察到持久性的CR（> 10個月）。
- "我們很高興看到SAR'579持續顯示出有前途的和持久的臨床效果，同時具有良好的安全性。正在進行的1/2期研究最近進展到2期階段，在其發展中達成了重要里程碑。我們期待這種多重特異性NK細胞結合劑的進一步進展，該結合劑具有使患者受益於各種血液癌症的巨大潛力。Innate Pharma的首席醫學官Sonia Quaratino博士表示：“這種多重特異性NK細胞結合劑具有巨大的潛力，可使患者受益於各種血液癌症。我們期待着其持續的進展。”,"說道Innate Pharma的首席醫療官Sonia Quaratino博士。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。